SUNSET, La., March 13, 2015 (GLOBE NEWSWIRE) -- 1 in 10 people suffer from depression, and prescriptions for antidepressants have increased 400% in the past two decades; yet, the patient compliance rates for these medications remains extremely low: 10% of patients won't even get the first prescription filled.
According to a review of antidepressant use published in Advances in Psychiatric Treatment, cumbersome side effects are a main reason patients simply don't stick to their therapy. Sexual dysfunction and weight rank as top reasons patients stop antidepressants. Non adherence rates increase with time, with 70% of patients stopping their prescribed therapy within 6 months.
While SSRIs continue to be the most commonly prescribed class of drugs for the treatment of depression, the side effects accompanying them are leading patients and providers to look for other alternatives.
JayMac Pharmaceuticals, makers of EnLyte, advanced generation RX folate therapy, are committed to educating on folate therapy as a solid choice in antidepressant treatment, where needed, without the side effects known to lead to patient noncompliance.
Folate therapy is recommended by the American Psychiatric Association's Treatment Guidelines for Major Depressive Disorder, and the APA CAM Guidelines, as an effective, safe, adjunctive choice that comes with little risk and has general health benefits.
EnLyte is an advanced generation prescription folate therapy containing 16 mgs. Delta Folate: a proprietary combination of diverse folates, all proven effective in treating depression, plus the necessary, brain-ready cofactors of B1, B2, B3, B6, B12, betaine, in addition to zinc, magnesium, vitamin C, and PS Gold Omega 3s. EnLyte is certified gluten free and artificial dye free. It is pregnancy category A and FDA-regulated. EnLyte is a natural choice that gives the brain the necessary components it needs to maximize neurotransmitter production.
EnLyte is used by psychiatrists nationwide as adjunctive therapy to SSRI/SNRI therapy, as research shows combining folate therapy with SSRI treatment from the start results in significantly better clinical outcomes: patients achieved remission of depression sooner with fewer side effects and better patient compliance. EnLyte is also used as monotherapy in certain instances.
EnLyte is paid for by many private insurance plans at an average copay of $45 per month, Tricare for $17 per month, many state Medicaid plans, and through mail order for $58 per month.
To learn more, visit www.EnLyteRx.Com or email us.
CONTACT: Angela Hall 850-602-1617 email@example.comSource:JayMac Pharmaceuticals(EnLyte)